Expert Reviews Treatment Landscape for Patients With Mantle Cell Lymphoma
Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the current treatment options for patients with mantle cell lymphoma (MCL).
MCL is a very complicated lymphoma, Leslie says. In the upfront setting, physicians should consider factors like age, comorbidities, and what is driving the lymphoma, such as a P53 abnormality. The treatment options in this setting include high-dose chemotherapy and autologous stem cell transplant.
For patients with MCL who are older and less fit, options include bendamustine/rituximab (Rituxan)-like regimens. In a rare subset of patients with MCL, the watch and wait approach could be appropriate, but this is less common in MCL than in other indolent lymphomas.
Overall, Leslie says that she encourages participation in clinical trials for MCL. There are many ongoing studies right now evaluating novel agents, BTK inhibitors, BCL2 inhibitors, combination regimens, and more.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
